Moreover, elderly or intensive chemotherapy-unfit AML patients treated with 5-azacytidine (AZA) and the BCL2 inhibitor venetoclax (VEN) exhibited higher levels of miR-182 promoter hypermethylation compared to normal controls [30]. Here, BCL2 is linked to acute myeloid leukemia.